GlassScriptPhysician profile
Jan C Prazak
NPI 1649488222
$2,261.99
in general payments reported to CMS, 2019-2025
23 companies · $579 in 2025
The $579 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $11.16 · 2021: $350 · 2022: $188 · 2023: $257 · 2024: $768 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,573 · Education: $31.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,572.68 |
| Education | $31.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $425.73 | 2019-2025 | |
| Boston Scientific Corporation | $371.06 | 2021-2025 | Compliance Endokit, Advanix Biliary, Dreamtome Rx 49 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $361.10 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $204.71 | 2022-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $151.69 | 2024-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $126.38 | 2024-2025 | Vowst, Zenpep |
| Genzyme Corporation | $109.05 | 2024 | |
| Nestle Healthcare Nutrition INC. | $64.63 | 2023 | |
| Ironwood Pharmaceuticals, INC | $60.95 | 2024 | |
| Redhill Biopharma INC. | $58.21 | 2021-2023 | Talicia, Aemcolo, Movantik |
| Phathom Pharmaceuticals, INC. | $45.39 | 2025 | Voquezna |
| Pfizer INC. | $41.33 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.98 | 2024 | Gattex, Eohilia |
| Ipsen Biopharmaceuticals, INC | $32.99 | 2024-2025 | Iqirvo |
| Lilly USA, LLC | $31.51 | 2024 | Omvoh |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $28.87 | 2024-2025 | |
| Daiichi Sankyo INC. | $20.58 | 2021 | |
| Merck Sharp & Dohme LLC | $20.06 | 2022 | |
| Braintree Laboratories, INC. | $19.56 | 2025 | Sutab, Suflave |
| Gilead Sciences, INC. | $19.34 | 2025 | |
| Olympus America INC. | $15.72 | 2021 | |
| Celltrion USA INC. | $15.15 | 2023 | Yuflyma |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Prazak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.